News & Events
Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis
- Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia and Related Disorders in Miami - GAITHERSBURG, Md., May 10, 2022 – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA [...]
Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma
Descartes-25 engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment Product generated from Company’s Part 1271-compliant Master Cell Bank of human umbilical cord Mesenchymal Stem Cells Fifth IND in [...]
Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors
Gaithersburg, Md., Dec. 14, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the appointment of five internationally recognized Senior Advisors to support [...]
Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
Former CMO Metin Kurtoglu, M.D., Ph.D., appointed as the Company’s first Chief Operating Officer Cartesian expands cGMP manufacturing facility to support growing clinical pipeline Gaithersburg, Md., Sept. 28, 2021 – Cartesian Therapeutics, a fully [...]
Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis
In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification and substantial improvement in Myasthenia Gravis Composite scale. Descartes-08 was [...]
Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies
Award increases NIH funding to $6.3 million to date from three independent NIH Institutes.Gaithersburg, MD, May 4, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today [...]
June 15-18, 2022, Moscone West Convention Center in San Francisco
June 15, 8:30 a.m. PT / 11:30 a.m. PT (available on the virtual meeting platform) – Dr. Murat Kalayoglu, President and Chief Executive Officer, participates as a panelist in Maryland Stem Cell Research Fund Focus Session, “Accelerating Cures – Translating Stem Cell Discoveries into Therapies.” In this Focus session, Maryland-based leaders in the field explore the latest breakthroughs and advances in stem cell disease modeling and tissue engineering approaches. Hear from Dr. Kalayoglu on creating, manufacturing and delivering cell therapies to patients with unmet medical needs.
mRNA-Based Therapeutics Summit
July 26-28, 2022, Hilton Boston
July 28, 12:00 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in the Unleashing the Power of mRNA Technology for CAR-T Therapies session, a presentation titled “Cell Therapy: In & Beyond Oncology.” Dr. Kurtoglu will discuss cell products engineered with RNA that express Chimeric Antigen Receptor (CAR) being tested in autoimmune disease and frontline oncology indications and the potential of RNA Cell Therapies as there is no limit to the number of cells that can be transfected with multiple RNAs and therapeutic functions.
July 28, 4:25 p.m. ET – Dr. Milos Miljkovic, Chief Medical Officer, participates in the Achieving a Successful Route to Equitable Distribution for mRNA-Based Therapeutics & Vaccines session and will lead a presentation titled “Achieving Equitable Access to CAR-T & Other Cellular Therapy Through RNA Engineering.” Dr. Miljkovic will focus on the advantages of RNA-engineered cellular therapy over DNA-based cell therapy. He will also discuss how Cartesian Therapeutics has successfully used three different mRNA-engineered cell therapy products in community clinics around the U.S., and the potential of RNA to make global distribution of effective clinical therapies more equitable.
Antibody Engineering & Therapeutics Europe
June 9, 2022, Postillion Hotel Amsterdam; Digital Experience: All Sessions Livestreamed June 7 – 9
June 9, 2022, 16:55 CET (10:55 a.m. ET) – Dr. Michael Singer presents at Informa’s Antibody Engineering & Therapeutics Conference in a session titled “RNA-Engineered Cell Therapies for Autoimmune Disease.” RNA cell therapies combine the potency of DNA-engineering (such as CAR T-cells) with the speed and manufacturability of RNA. RNA offers another key advantage: controllable pharmacokinetics. In our clinical trials, RNA cell therapies have been remarkably safe. We have administered them in outpatient clinics, with no need for preconditioning chemotherapy. This benefit:risk profile has allowed us to develop therapies for autoimmune disease, including Descartes-08, an anti-BCMA CAR T-cell, for autoantibody-mediated diseases like myasthenia gravis.
Maryland Tech Council Industry Awards
May 12, 2022, Bethesda North Marriott Hotel & Conference Center
May 12, 5:30 p.m. ET – Cartesian has been selected as a finalist for the Emerging Life Sciences Company of the Year award for the Maryland Tech Council’s Industry Awards Celebration. The Industry Awards Celebration hosts attendees from the life sciences and technology industries and is Maryland’s largest and most prestigious award ceremony of its kind.
14th MGFA International Conference On Myasthenia And Related Disorders
May 10-12, 2022, Hyatt Regency Miami
May 10, 10:50 a.m. ET – Dr. Volkan Granit, Neurologist at the University of Miami Health System, will present clinical research of Cartesian’s first CAR T-cell therapy for the treatment of generalized myasthenia gravis (GMG). Descartes-08 contains autologous CD8+ T-cells engineered with RNA chimeric antigen receptors (CARs) that bind B-cell maturation antigen (BCMA). BCMA is expressed ubiquitously by plasma cell clones that produce pathogenic autoantibodies. Descartes-08 binds and kills these cells, eliminating the autoantibody source.
May 10, 6:00 p.m. ET – Cartesian will present a poster on clinical research from its Phase 1a/2a study for Descartes-08 in patients with generalized Myasthenia Gravis. Patients were treated with increasing doses to determine the safety and preliminary efficacy.
January 25-28, 2022, Miami Beach Convention Center
Jan. 27, 2:05 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in a session titled “Delivery Solutions and Alternatives for Gene and Cell Therapy,” with a specific emphasis on RNA Cell Therapy in And Beyond Oncology.
Jan. 28, 11:05 a.m. ET – Dr. Emily English, Director of Quality, participates in a session titled “Achieving Best Practice in Quality Control and Assurance,” with a focus on providing an overview of our experience building and evolving quality management systems in an early-stage cell therapy company.
January 20, 2022
9:00 a.m. ET – Dr. Murat Kalayoglu joins John Stanford, Executive Director at Incubate, in a fireside chat titled “Protecting Innovation: Putting Patients First.” The Maryland Tech Council’s Advocacy Summit will bring industry leaders together to build meaningful relationships with elected officials, provide information about policies that can transform millions of lives and tips on how your advocacy with policymakers in Annapolis can make a difference.
Opportunities for Growth: Biotech Land Use Update
October 22, 2021
Dr. Murat Kalayoglu is joined by other Montgomery County owners and developers, discussing how best to foster the lab space and talent in the area. The discussion focused on nurturing and leveraging the resources of Montgomery County to retain and expand the biotech industry, as well as other growth opportunities in the County.
October 5, 2021
9:00 a.m. – Dr. Michael Singer participates in a panel titled “Engineered Cell Therapies: Increasingly Complex Product Development.” In this panel, Dr. Singer will explore how Cartesian is developing innovative approaches for novel cell therapeutics for the treatment of a growing list of intractable diseases. The presentation will be followed by a short Q&A session with the panelists.
11:00 a.m. – Dr. Murat Kalayoglu moderates a panel titled “Cell and Gene Therapy: Beyond Oncology.” The panel discusses the applications of cell therapy beyond the treatment of advanced cancers. Specific examples include the use of cell & gene therapy for the treatment of autoimmune disorders such as myasthenia gravis, respiratory diseases such as ARDS and COVID-19, and rare genetic disorders such as XMEN disease. Ex-vivo cell modification strategies are compared between different approaches and disease indications. Potential benefits of these novel approaches are weighed against treatment risks and costs.
September 2, 2021
12:00 p.m. – Dr. Murat Kalayoglu provides a corporate presentation and participates in a Q&A session focused on deploying the company’s RNA Armory® platform to equip cell immunotherapies beyond oncology. He discusses the biological basis and cell therapy engineering approaches to combat respiratory and autoimmune disorders, shares experiences in developing a cGMP manufacturing facility in-house for RNA-based cell therapies, highlights the distinct advantages of an RNA-based engineering platform to targetcells to diseased tissues to deliver any combination of therapies, and provides updates on phase I/II clinical trials for investigational therapies in multiple myeloma, myasthenia gravis, and acute respiratory distress syndrome linked to COVID-19.
2:00 p.m. – Dr. Murat Kalayoglu participates in a panel reflecting on historic developments in the industry, and the ‘why’ behind CAR-TCR’s launch into oncology and discussing the relative advantages and challenges of expanding these technologies to indications beyond oncology.
Maryland Tech Council Industry Awards Celebration
May 20, 2021
Cartesian has been selected as a finalist of the “Emerging Life Sciences Company of the Year” and Dr. Murat Kalayoglu has been selected as a finalist for the “Chief Executive Officer of the Year – Life Sciences” by the Maryland Tech Council. The winners of the awards will be announced at the Industry Awards Celebration on May 20. The event celebrates individuals and companies in the government contracting, life sciences and technology industries that have made a significant impact in their respective industry.
GEN Panel: Manufacturing CAR-T Therapies
March 24, 2021
In this panel, Dr. Metin Kurtoglu, Cartesian’s Chief Medical Officer, speaks to Cartesian’s expertise in manufacturing and characterizing the function and potency of CAR-T cell products using its wholly-owned, state-of-the-art GMP manufacturing facility.
American Association of Neuromuscular & Electrodiagnostic Medicine Spring Virtual Conference
March 2- March 5, 2021
Dr. Kelly Gwanthemey, Assistant Prof of Neurology at Virginia Commonwealth University, presents on emerging therapeutics in myasthenia gravis, including Cartesian’s work with an mRNA cell therapy, Descartes-08.
Sixth Annual 2020 BioHealth Capital Region Virtual Forum
October 19, 2020
Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, participated in a panel titled, “Strengths of the Regions – Cutting Edge Therapies.” The panel brought together leaders from three companies to discuss their disruptive pipelines, the strength of the region and challenges brought by the COVID-19 pandemic.
September 16, 2020
Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, joins a panel hosted by Martin Rosendale, CEO of the Maryland Tech Council. On this CapitalM ZoomCast Live event Dr. Kalayoglu discusses Cartesian and its role in the Maryland science eco-system.